



New Data Highlighting the Powerful Performance of RosettaGX Reveal™ in Identifying Medullary Thyroid Cancer to be Presented at the AACE 2017 Annual Meeting

Demonstrates Accuracy of the Assay in the Pre-Operative Diagnosis of Thyroid Nodules with Indeterminate Cytology

PHILADELPHIA and REHOVOT, Israel (April 27, 2017) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces that new data demonstrating the accuracy of RosettaGX Reveal™ (Reveal) in the pre-operative diagnosis of medullary thyroid carcinoma (MTC) in Fine-needle aspiration (FNA) will be presented at the American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific and Clinical Congress being held May 3-7, 2017 in Austin, Texas.

While MTC accounts for less than 5% of all thyroid malignancies, it causes a disproportionate number of thyroid cancer-related deaths. Fine-needle aspiration (FNA) is an important tool for the diagnosis of thyroid cancer, however, in some cases an MTC diagnosis is not suspected based on FNA cytology alone. The new data characterizes Reveal's performance in the clinical setting with regard to MTC and presents specific clinical cases that demonstrate the benefits of using the Reveal assay.

The study authors concluded, "RosettaGX Reveal can accurately detect medullary carcinoma using stained FNA smears or ThinPrep samples, even in cytologically indeterminate samples. The Reveal assay is suggested in patients with an indeterminate cytology diagnosis and can play a valuable role in the detection of MTC, and hopefully, provide for more favorable outcome for patients."

The following RosettaGX Reveal abstract will be presented during AACE 2017:

Title: Validity of RosettaGX Reveal for the Accurate Diagnosis of Pre-Operative Medullary Thyroid Carcinoma Utilizing FNA Smear
Poster: Poster #1126
Presenter: Nicole A. Massoll, M.D. (University of Arkansas and Rosetta Genomics, and Elias Stephan, M.D. (Texas Thyroid and Endocrine Center)
Date/Time: Saturday, May 6th at 10:00 am – 11:00 am CDT

“We are delighted to have new data validating the accuracy of Reveal in diagnosing MTC presented at AACE, particularly given the life-threatening nature of this type of thyroid carcinoma,” noted Nicole Massoll, M.D., Lab and Medical Director at Rosetta Genomics. “These data build upon our earlier clinical and analytical validation data already published in prestigious peer-review journals that support the use of Reveal in the diagnosis of indeterminate thyroid cancer.”

“In addition to superior performance data, Reveal is the only test that allows clinicians to analyze the exact same cells that were used to make the initial indeterminate cytology diagnosis, which avoids the need for additional biopsies and also reduces the risk of sampling error, a common and significant problem with other molecular diagnostic tests,” stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.

About Rosetta Genomics

Rosetta is pioneering the field of molecular diagnostics by offering rapid and accurate diagnostic information that enables physicians to make more timely and informed treatment decisions to improve patient care. Rosetta has developed a portfolio of unique diagnostic solutions for endocrinologists, oncologists, urologists, cytopathologists, and other specialists to help them deliver better care to their patients. RosettaGX Reveal™, a Thyroid microRNA Classifier for indeterminate thyroid nodules, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company’s Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s most recently filed Annual Report on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Rosetta Genomics Contact:
Ken Berlin, President & CEO
(267) 298-1159
investors@rosettagx.com

Rosetta Genomics Investor Contact:
LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com

